Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Mak DH"'
Autor:
Zeng, Z, Wang, R-Y, Qiu, YH, Mak, DH, Coombes, K, Yoo, SY, Zhang, Q, Jessen, K, Liu, Y, Rommel, C, Fruman, DA, Kantarjian, HM, Kornblau, SM, Andreeff, M, Konopleva, M
Publikováno v:
Zeng, Z; Wang, R-Y; Qiu, YH; Mak, DH; Coombes, K; Yoo, SY; et al.(2016). MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. ONCOTARGET, 7(34), 55083-55097. doi: 10.18632/oncotarget.10397. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/6w11w157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::c2093ff61e896234fc13a2faf83206c4
http://www.escholarship.org/uc/item/6w11w157
http://www.escholarship.org/uc/item/6w11w157
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ, Mak, D H, Wang, R-Y, Schober, W D, Konopleva, M, Cortes, J, Kantarjian, H, Andreeff, M, Carter, B Z
Publikováno v:
Leukemia (08876924); Apr2012, Vol. 26 Issue 4, p788-794, 7p
Autor:
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M, Schimmer, Aaron D, Estey, Elihu H
Publikováno v:
Journal of Clinical Oncology; 10/1/2009, Vol. 27 Issue 28, p4741-4746, 6p
Autor:
Konopleva M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Milella M; Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy., Ruvolo P; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Watts JC; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Ricciardi MR; Hematology, Department of Biotecnologie Cellulari ed Ematologia, Sapienza, University of Rome, Rome, Italy., Korchin B; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Teresa M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Bornmann W; Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Tsao T; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Bergamo P; Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Chen W; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., McCubrey J; Department of Microbiology & Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA., Tafuri A; Hematology, Department of Biotecnologie Cellulari ed Ematologia, Sapienza, University of Rome, Rome, Italy., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.
Publikováno v:
Leukemia [Leukemia] 2024 Sep; Vol. 38 (9), pp. 2072.
Autor:
Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. bicarter@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ke B; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ordentlich P; Syndax, Waltham, MA., McGeehan GM; Syndax, Waltham, MA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. mandreef@mdanderson.org.
Publikováno v:
Haematologica [Haematologica] 2023 Sep 01; Vol. 108 (9), pp. 2513-2519. Date of Electronic Publication: 2023 Sep 01.
Autor:
Shi W; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wang Y; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhao Y; Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Kim JJ; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Biology, Colby College, Waterville, ME 04901, USA., Li H; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Meng C; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Chen F; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mak DH; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Van V; Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Leo J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA., St Croix B; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Aparicio A; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhao D; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Publikováno v:
Science translational medicine [Sci Transl Med] 2023 May 10; Vol. 15 (695), pp. eadf6724. Date of Electronic Publication: 2023 May 10.
Autor:
Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang Q; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kuruvilla VM; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang X; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Battula VL; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva M; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hughes PE; Oncology Research, Amgen Inc., Thousand Oaks, California., Chen X; Oncology Research, Amgen Inc., Thousand Oaks, California., Morrow PK; Amgen Inc., Thousand Oaks, California., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 879-889.
Autor:
Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mu H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang X; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dettman EJ; Eutropics, Cambridge, MA, USA., Cardone M; Eutropics, Cambridge, MA, USA., Zernovak O; Daiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan., Seki T; Daiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org.
Publikováno v:
Haematologica [Haematologica] 2020 May; Vol. 105 (5), pp. 1274-1284. Date of Electronic Publication: 2019 Aug 01.
Autor:
Han L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China., Zhang Q; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dail M; Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA., Shi C; Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China., Cavazos A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo VR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim E; Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA., Rahmani M; College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE.; Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Mak DH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jin SS; AbbVie Inc., North Chicago, IL, USA., Chen J; AbbVie Inc., North Chicago, IL, USA., Phillips DC; AbbVie Inc., North Chicago, IL, USA., Koller PB; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jacamo R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grant S; Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Leverson JD; AbbVie Inc., North Chicago, IL, USA., Sampath D; Department of Translational Oncology, Genentech, South San Francisco, CA, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA mkonople@mdanderson.org.
Publikováno v:
Haematologica [Haematologica] 2020 Mar; Vol. 105 (3), pp. 697-707. Date of Electronic Publication: 2019 May 23.